The Multiplex Model of the Genetics of Alzheimer's Disease

Overview

Journal Nat Neurosci

Date 2020 Mar 1

PMID 32112059

Citations 223

Authors

Rebecca Sims

Matthew Hill

Julie Williams

Affiliations

Soon will be listed here.

Abstract

Genes play a strong role in Alzheimer's disease (AD), with late-onset AD showing heritability of 58-79% and early-onset AD showing over 90%. Genetic association provides a robust platform to build our understanding of the etiology of this complex disease. Over 50 loci are now implicated for AD, suggesting that AD is a disease of multiple components, as supported by pathway analyses (immunity, endocytosis, cholesterol transport, ubiquitination, amyloid-β and tau processing). Over 50% of late-onset AD heritability has been captured, allowing researchers to calculate the accumulation of AD genetic risk through polygenic risk scores. A polygenic risk score predicts disease with up to 90% accuracy and is an exciting tool in our research armory that could allow selection of those with high polygenic risk scores for clinical trials and precision medicine. It could also allow cellular modelling of the combined risk. Here we propose the multiplex model as a new perspective from which to understand AD. The multiplex model reflects the combination of some, or all, of these model components (genetic and environmental), in a tissue-specific manner, to trigger or sustain a disease cascade, which ultimately results in the cell and synaptic loss observed in AD.

Citing Articles

Summarizing attributable factors and evaluating risk of bias of Mendelian randomization studies for Alzheimer's dementia and cognitive status: a systematic review and meta-analysis.

Meng X, Li X, Cao M, Dong J, Wang H, Cao W Syst Rev. 2025; 14(1):61.

PMID: 40082927 PMC: 11905674. DOI: 10.1186/s13643-025-02792-5.

Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology.

Dhariwal R, Jain M, Mir Y, Singh A, Jain B, Kumar P Front Med (Lausanne). 2025; 12:1522223.

PMID: 39963432 PMC: 11831571. DOI: 10.3389/fmed.2025.1522223.

Genetic Prοpensity for Different Aspects of Dementia Pathology and Cognitive Decline in a Community Elderly Population.

Sampatakakis S, Mourtzi N, Hatzimanolis A, Koutsis G, Charisis S, Gkelmpesi I Int J Mol Sci. 2025; 26(3).

PMID: 39940679 PMC: 11817854. DOI: 10.3390/ijms26030910.

A Novel Missense Variant in SORBS2 Is Causative With Familial Alzheimer's Disease.

Wang Q, Wang S, Cao S, Wang Q, Wei Y, Li Y CNS Neurosci Ther. 2025; 31(2):e70256.

PMID: 39912518 PMC: 11800137. DOI: 10.1111/cns.70256.

The genetic landscape of early-onset Alzheimer's disease in China.

Qin W, Li F, Liu W, Li Y, Cao S, Wei Y Alzheimers Dement. 2025; 21(2):e14486.

PMID: 39907198 PMC: 11851144. DOI: 10.1002/alz.14486.

References

Goate A, Chartier-Harlin M, Mullan M, Brown J, Crawford F, Fidani L . Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349(6311):704-6. DOI: 10.1038/349704a0. View

Sherrington R, Rogaev E, Liang Y, Rogaeva E, Levesque G, Ikeda M . Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995; 375(6534):754-60. DOI: 10.1038/375754a0. View

Rogaev E, Sherrington R, Rogaeva E, Levesque G, Ikeda M, Liang Y . Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995; 376(6543):775-8. DOI: 10.1038/376775a0. View

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

Ricciarelli R, Fedele E . The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind. Curr Neuropharmacol. 2017; 15(6):926-935. PMC: 5652035. DOI: 10.2174/1570159X15666170116143743. View

Doody R, Farlow M, Aisen P . Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014; 370(15):1460. DOI: 10.1056/NEJMc1402193. View

Honig L, Vellas B, Woodward M, Boada M, Bullock R, Borrie M . Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med. 2018; 378(4):321-330. DOI: 10.1056/NEJMoa1705971. View

Galimberti D, Scarpini E . Disease-modifying treatments for Alzheimer's disease. Ther Adv Neurol Disord. 2011; 4(4):203-16. PMC: 3131171. DOI: 10.1177/1756285611404470. View

Yiannopoulou K, Papageorgiou S . Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord. 2013; 6(1):19-33. PMC: 3526946. DOI: 10.1177/1756285612461679. View

10.

Jagust W . Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci. 2018; 19(11):687-700. PMC: 7032048. DOI: 10.1038/s41583-018-0067-3. View

11.

Rajan K, Wilson R, Weuve J, Barnes L, Evans D . Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology. 2015; 85(10):898-904. PMC: 4560057. DOI: 10.1212/WNL.0000000000001774. View

12.

Rosenblum W . Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol Aging. 2013; 35(5):969-74. DOI: 10.1016/j.neurobiolaging.2013.10.085. View

13.

Gatz M, Reynolds C, Fratiglioni L, Johansson B, Mortimer J, Berg S . Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006; 63(2):168-74. DOI: 10.1001/archpsyc.63.2.168. View

14.

Wingo T, Lah J, Levey A, Cutler D . Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol. 2011; 69(1):59-64. PMC: 3332307. DOI: 10.1001/archneurol.2011.221. View

15.

Saunders A, Schmader K, Breitner J, Benson M, Brown W, Goldfarb L . Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet. 1993; 342(8873):710-1. DOI: 10.1016/0140-6736(93)91709-u. View

16.

Strittmatter W, Saunders A, Schmechel D, Pericak-Vance M, Enghild J, Salvesen G . Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90(5):1977-81. PMC: 46003. DOI: 10.1073/pnas.90.5.1977. View

17.

Corder E, Saunders A, Risch N, Strittmatter W, Schmechel D, Gaskell Jr P . Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994; 7(2):180-4. DOI: 10.1038/ng0694-180. View

18.

Liao F, Yoon H, Kim J . Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. Curr Opin Lipidol. 2016; 28(1):60-67. PMC: 5213812. DOI: 10.1097/MOL.0000000000000383. View

19.

Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn M . apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008; 118(12):4002-13. PMC: 2582453. DOI: 10.1172/JCI36663. View

20.

Verghese P, Castellano J, Holtzman D . Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 2011; 10(3):241-52. PMC: 3132088. DOI: 10.1016/S1474-4422(10)70325-2. View